177Lu peptide targets uPAR receptor for colorectal cancer treatment

ChangeBridge: Patent Grants - Peptides (C07K)

Published March 31st, 2026

Detected March 31st, 2026

Summary

USPTO granted patent US12589171B2 to TRT INNOVATIONS APS covering a 177-Lu labeled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) for treatment of cancers with high uPAR expression, particularly colorectal cancer. The patent includes 9 claims and lists inventors Andreas Kjaer, Morten Persson, and Michael Ploug.

View original document View source feed page

What changed

USPTO issued Patent No. US12589171B2 to TRT INNOVATIONS APS for a therapeutic composition comprising a 177-Lu labeled peptide targeting the uPAR receptor. The patent covers methods of treating colorectal cancer and other cancers associated with high uPAR expression by administering an effective amount of the labeled peptide. Filing date was January 7, 2021, with Application No. 17144067.

This is a routine patent grant conveying intellectual property rights. Pharmaceutical companies developing radiopharmaceuticals for oncology indications should review the patent claims to assess potential licensing needs or freedom-to-operate concerns. No compliance deadlines or regulatory actions are associated with this grant.

Source document (simplified)

← USPTO Patent Grants

177-Lu labeled peptide for site-specific uPAR-targeting

Grant US12589171B2 Kind: B2 Mar 31, 2026

Assignee

TRT INNOVATIONS APS

Inventors

Andreas Kjaer, Morten Persson, Michael Ploug

Abstract

There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.